ADC Therapeutics Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
193
- Stock Symbol
-
ADCT
- Investments
-
1
- Share Price
-
$1.28
- (As of Friday Closing)
ADC Therapeutics General Information
Description
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Contact Information
Website
www.adctherapeutics.comCorporate Office
- Biopole
- Route de la Corniche 3B
- 1066 Epalinges
- Switzerland
Corporate Office
- Biopole
- Route de la Corniche 3B
- 1066 Epalinges
- Switzerland
ADC Therapeutics Timeline
ADC Therapeutics Stock Performance
As of 20-Nov-2026, ADC Therapeutics’s stock price is $1.28. Its current market cap is $180M with 141M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.28 | $1.30 | $0.78 - $4.98 | $180M | 141M | 1.54M | -$0.52 |
ADC Therapeutics Financials Summary
As of 30-Sep-2026, ADC Therapeutics has a trailing 12-month revenue of $84.9M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 54,211 | 319,814 | 42,691 | (53,011) |
| Revenue | 84,873 | 81,357 | 70,837 | 69,558 |
| EBITDA | (36,829) | (96,909) | (114,921) | (156,367) |
| Net Income | (81,246) | (142,623) | (157,846) | (240,053) |
| Total Assets | 255,863 | 323,150 | 321,980 | 354,782 |
| Total Debt | 116,104 | 117,024 | 122,998 | 124,377 |
ADC Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ADC Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
ADC Therapeutics Comparisons
Industry
Financing
Details
ADC Therapeutics Competitors (74)
One of ADC Therapeutics’s 74 competitors is Aura Biosciences, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aura Biosciences | Formerly VC-backed | Boston, MA | ||||
| Vor Biopharma | Formerly VC-backed | Boston, MA | ||||
| BeOne Medicines | Formerly PE-Backed | Beijing, China | ||||
| Gyre Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Gilead | Formerly VC-backed | Foster City, CA |
ADC Therapeutics Patents
ADC Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026215517-A1 | Antibody-drug conjugates comprising exatecan | Pending | 11-Apr-2025 | ||
| GB-202408679-D0 | An insulation apparatus | Inactive | 17-Jun-2024 | ||
| US-20250186604-A1 | Anti-psma antibody conjugates | Pending | 06-Dec-2023 | ||
| AU-2024394903-A1 | Anti-psma antibody drug conjugates comprising exatecan | Pending | 06-Dec-2023 | ||
| EP-4820062-A1 | Anti-psma antibody drug conjugates comprising exatecan | Pending | 06-Dec-2023 | A61K47/68037 |
ADC Therapeutics Signals
ADC Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ADC Therapeutics Investments (1)
ADC Therapeutics’s most recent deal was a Joint Venture with Overland ADCT BioPharma. The deal was made on 14-Dec-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Overland ADCT BioPharma | 14-Dec-2020 | Joint Venture | Drug Discovery |
ADC Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.62 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
ADC Therapeutics FAQs
-
When was ADC Therapeutics founded?
ADC Therapeutics was founded in 2011.
-
Where is ADC Therapeutics headquartered?
ADC Therapeutics is headquartered in Epalinges, Switzerland.
-
What is the size of ADC Therapeutics?
ADC Therapeutics has 193 total employees.
-
What industry is ADC Therapeutics in?
ADC Therapeutics’s primary industry is Drug Discovery.
-
Is ADC Therapeutics a private or public company?
ADC Therapeutics is a Public company.
-
What is ADC Therapeutics’s stock symbol?
The ticker symbol for ADC Therapeutics is ADCT.
-
What is the current stock price of ADC Therapeutics?
As of 20-Nov-2026 the stock price of ADC Therapeutics is $1.28.
-
What is the current market cap of ADC Therapeutics?
The current market capitalization of ADC Therapeutics is $180M.
-
What is ADC Therapeutics’s current revenue?
The trailing twelve month revenue for ADC Therapeutics is $84.9M.
-
Who are ADC Therapeutics’s competitors?
Aura Biosciences, Vor Biopharma, BeOne Medicines, Gyre Therapeutics, and Gilead are some of the 74 competitors of ADC Therapeutics.
-
What is ADC Therapeutics’s annual earnings per share (EPS)?
ADC Therapeutics’s EPS for 12 months was -$0.52.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process